表观遗传药物在焦虑症治疗中的潜在作用。

The Potential Role of Epigenetic Drugs in the Treatment of Anxiety Disorders.

作者信息

Peedicayil Jacob

机构信息

Department of Pharmacology & Clinical Pharmacology, Christian Medical College, Vellore, India.

出版信息

Neuropsychiatr Dis Treat. 2020 Mar 2;16:597-606. doi: 10.2147/NDT.S242040. eCollection 2020.

DOI:10.2147/NDT.S242040

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7060022/

Abstract

There is increasing evidence that abnormalities in epigenetic mechanisms of gene expression contribute to the pathogenesis of anxiety disorders (ADs). This article discusses the role of epigenetic mechanisms of gene expression in the pathogenesis of ADs. It also discusses the data so far obtained from preclinical and clinical trials on the use of epigenetic drugs for treating ADs. Most drug trials investigating the use of epigenetic drugs for treating ADs have used histone deacetylase inhibitors (HDACi). HDACi are showing favorable results in both preclinical and clinical drug trials for treating ADs. However, at present the mode of action of HDACi in ADs is not clear. More work needs to be done to elucidate how epigenetic dysregulation contributes to the pathogenesis of ADs. More work also needs to be done on the mode of action of HDACi in alleviating the signs and symptoms of ADs.

摘要

越来越多的证据表明，基因表达表观遗传机制的异常与焦虑症（ADs）的发病机制有关。本文讨论了基因表达表观遗传机制在ADs发病机制中的作用。还讨论了目前从使用表观遗传药物治疗ADs的临床前和临床试验中获得的数据。大多数研究使用表观遗传药物治疗ADs的药物试验都使用了组蛋白去乙酰化酶抑制剂（HDACi）。HDACi在治疗ADs的临床前和临床药物试验中均显示出良好效果。然而，目前HDACi在ADs中的作用模式尚不清楚。需要开展更多工作来阐明表观遗传失调如何导致ADs的发病机制。还需要对HDACi缓解ADs体征和症状的作用模式开展更多研究。